A Study of Camrelizumab in Combination With Anlotinib in Subjects Advanced Ovarian Clear Cell Carcinoma
Clinical trial NCT05600998 · UNKNOWN
Trial details
- NCT number
- NCT05600998
- Sponsor
- Peking University Third Hospital
- Status
- UNKNOWN
- Phase
- Not Applicable
- Study type
- INTERVENTIONAL
- Start date
- 2022-10-30
- Primary completion
- 2023-09-30
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.